Skip to main content
. 2023 Mar 20;6(3):e233646. doi: 10.1001/jamanetworkopen.2023.3646

Table 3. Patient Characteristics in the Sensitivity Analysis Before and After 1:1 PS Matching.

Characteristic Before PS matching After PS matching
Patients, No. (%) SMD Patients, No. (%) SMD
Metformin (n = 104 471) Sulfonylurea (n = 8277) Metformin (n = 8277) Sulfonylurea (n = 8277)
Age, mean (SD), y 59.4 (11.1) 66.3 (12.5) 0.584 66.1 (11.9) 66.3 (12.5) 0.019
Sex
Female 45 151 (43.2) 3144 (38.0) 0.107 3085 (37.3) 3144 (38.0) 0.015
Male 59 320 (56.8) 5133 (62.0) 5192 (62.7) 5133 (62.0)
Race and ethnicity
Asian 5713 (5.5) 356 (4.3) 0.123 353 (4.3) 356 (4.3) 0.029
Black 11 719 (11.2) 1054 (12.7) 988 (11.9) 1054 (12.7)
Hispanic 15 160 (14.5) 972 (11.7) 1009 (12.2) 972 (11.7)
White 63 766 (61.0) 5088 (61.5) 5142 (62.1) 5088 (61.5)
Unknown 8113 (7.8) 807 (9.7) 785 (9.5) 807 (9.7)
Education
<12th Grade 877 (0.8) 103 (1.2) 0.194 74 (0.9) 103 (1.2) 0.162
High school diploma 30 030 (28.7) 2796 (33.8) 2341 (28.3) 2796 (33.8)
<Bachelor’s degree 53 750 (51.4) 3992 (48.2) 4255 (51.4) 3992 (48.2)
≥Bachelor’s degree 13 875 (13.3) 729 (8.8) 1024 (12.4) 729 (8.8)
Unknown 5939 (5.7) 657 (7.9) 583 (7.0) 657 (7.9)
Charlson comorbidity score
0 70 374 (67.4) 4285 (51.8) 0.424 4227 (51.1) 4285 (51.8) 0.018
1-2 27 082 (25.9) 2383 (28.8) 2428 (29.3) 2383 (28.8)
3-4 5070 (4.9) 985 (11.9) 1012 (12.2) 985 (11.9)
5-6 1003 (1.0) 366 (4.4) 356 (4.3) 366 (4.4)
>6 942 (0.9) 258 (3.1) 254 (3.1) 258 (3.1)
Charlson comorbidity score, mean (SD) 0.6 (1.3) 1.3 (2.1) 0.413 1.3 (2.0) 1.3 (2.1) 0.018
Treatment duration, mean (SD), mo 24.4 (28.1) 19.8 (26.1) 0.169 18.4 (24.0) 19.8 (26.1) 0.058
Follow-up time, mean (SD), mo 31.9 (33.1) 32.4 (36.6) 0.013 28.8 (31.7) 32.4 (36.6) 0.104

Abbreviations: PS, propensity score; SMD, standardized mean difference.